Search clinical trials for: Placebo (insulin glargine)

Total 56004 results

Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany
Sanofi

Terminated

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Hungary
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy (INITIATE)

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Vanderbilt University Medical Center
Sanofi

Completed

Characteristics of Glargine in Type 2 Diabetics

Type 2 Diabetes

United States
Sanofi

Completed

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus

Type 1 Diabetes Mellitus

Germany
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
Sanofi

Completed

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Diabetes Mellitus Type 2

Germany
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Johns Hopkins University

Terminated

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

United States
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Sanofi

Terminated

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction (INTENSIVE)

AMI

Canada, Brazil, United States, Argentina, Mexico
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus (EDITION JP II)

Type 2 Diabetes Mellitus

Japan
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (EDITION IV)

Type 1 Diabetes Mellitus

United States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Lannett Company, Inc.
Parexel; FARMOVS (Pty) Ltd

Completed

A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

South Africa
Indonesia University

Completed

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus

Indonesia
Sanofi

Completed

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Type 2 Diabetes Mellitus

India
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Canada, Denmark, Hungary, Serbia, Germany, Greece, Romania, Estonia, Norway
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Netherlands, Hungary, France, Bulgaria, Canada, Romania
Novo Nordisk A/S

Completed

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes

India, Serbia, Bulgaria, Australia, Korea, Republic of, Thailand, Turkey, United Arab Emirates, Hungary
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Sweden, Malaysia, France, Netherlands, India, Argentina, South Africa, Romania, Former Serbia and Montenegro, Austria, Czech Republic, Philippines, Mexico
Novo Nordisk A/S

Recruiting

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Obesity | Diabetes Mellitus, Type 2

United States, Spain, Portugal, Italy, Greece, Romania, Slovakia, Czechia, South Africa, Ukraine
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

Type 2 Diabetes Mellitus

United States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Emory University

Completed

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Diabetes | Diabetes Mellitus, Type 1

Germany

3

Subscribe